Nebenwirkungen der neuen Antidepressiva

Der steigende Einsatz neuerer Antidepressiva liegt u. a. an deren geringerer Toxizität. Dennoch gibt es auch mit diesen Substanzen Nebenwirkungen – zwar seltener, aber dennoch potenziell gefährlich. Vor der Auswahl des passenden Antidepressivums steht deshalb eine ausführliche Anamnese und Aufklärung. Mit Kenntnis der Neben- und Wechselwirkungen mit anderen Medikamenten lassen sich der Behandlungserfolg optimieren und die Adhärenz fördern.

One reason for the increasing use of new antidepressant drugs is due to a decreased toxicity compared to older agents. Nevertheless, there are still potentially dangerous side effects important to be considered. To improve treatment outcome it is therefore advantageous to obtain a detailed medical history, as well as to give specific information about the mechanisms of action of antidepressants before choosing the appropriate drug. Communicating known side-effects to patients comprehensively can improve treatment and medication adherence.

Schlüsselwörter

Nebenwirkungen - Antidepressiva - Neurotransmitter

Keywords

side effects - Antidepressants - neurotransmitter

• Literatur

• 1 Seetal D, Bauer M, Mitchell P. Monitoring for antidepressantassociated adverse events in the treatment of patients with major depressive disorder: An International Consensus Statement. World J Biol Psychiatry. 2017 ; in revision
• 2 Warner-Schmidt J. 3215
• 3 Albert PR, Benkelfat C, Descarries L. The neurobiology of depression- revisiting the serotonin hypothesis. I. Cellular and molecular mechanisms. Philos Trans R Soc B Biol Sci 2012; 367: 2378-2381 . doi:10.1098/rstb.2012.0190
• 4 Coupland C, Hill T, Morriss R. et al. Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database. BMJ 2016; 352: i1350 . doi:10.1136/bmj.i1350
• 5 Castro VM, Clements CC, Murphy SN. et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ 2013; 346: f288-f288 . doi:10.1136/bmj.f288
• 6 Vitiello B, Ordóñez AE. Pharmacological treatment of children and adolescents with depression. Expert Opin Pharmacother 2016; 17: 2273-2279
• 7 Bismuth-Evenzal Y, Gonopolsky Y, Gurwitz D. et al. Decreased serotonin content and reduced agonist-induced aggregation in platelets of patients chronically medicated with SSRI drugs. J Affect Disord 2012; 136: 99-103 . doi:10.1016/j.jad.2011.08.013
• 8 Auerbach AD, Vittinghoff E, Maselli J. et al. Perioperative use of selective serotonin reuptake inhibitors and risks for adverse outcomes of surgery. JAMA Intern Med; 2013; 173: 1075-1081 . doi:10.1001/jamainternmed.2013.714
• 9 Muluk V, Cohn SL, Whinney CM. Perioperative medication management. 2017 . Im Internet: https://www.uptodate.com/contents/perioperative-medication-management; Stand: 15.08.2017
• 10 Hoyer D, Clarke DE, Fozard JR. et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994; 46: 157-203 . Im Internet: http://pharmrev.aspetjournals.org/content/46/2/157.full.pdf
• 11 Esposito E. Serotonin-dopamine interaction as a focus of novel antidepressant drugs. Curr Drug Targets 2006; 7: 177-185 . Im Internet: http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1389-4501&volume=7&issue=2&spage=177
• 12 Assem-Hilge E, Kasper S. Psychopharmaka und sexuelle Dysfunktion. Neurol Neurochir Psychiatr 2005; 6: 30-36
• 13 Liu BA, Mittmann N, Knowles SR. et al. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. CMAJ 1996; 155: 519-527
• 14 Waterhouse BD, Sessler FM, Cheng JT et al. . New evidence for a gating action of norepinephrine in central neuronal circuits of mammalian brain. Brain Res Bull 1988; 21: 425-432
• 15 Stone EA, Zhang Y, Rosengarten H. et al. Brain alpha 1-adrenergic neurotransmission is necessary for behavioral activation to environmental change in mice. Neurosci 1999; 94: 1245-1252
• 16 Benkert O, Hippius H, Fehr C. Kompendium der Psychiatrischen Pharmakotherapie. Heidelberg, Berlin: Springer; 2011. : 713
• 17 Alcaro A, Huber R, Panksepp J. Behavioral functions of the mesolimbic dopaminergic system: An affective neuroethological perspective. Brain Res Rev 2007; 56: 283-321 . doi:10.1016/j.brainresrev.2007.07.014
• 18 Nestler EJ, Hyman SE, Malenka RC. Molecular Neuropharmacology: a Foundation for clinical Neuroscience. New York: McGraw-Hill Medical; 2009
• 19 Leggio GM, Salomone S, Bucolo C. et al. Dopamine D(3) receptor as a new pharmacological target for the treatment of depression. Eur J Pharmacol 2013; 719: 25-33 . Im Internet: http://ac.els-cdn.com/S001429991300544X/1-s2.0-S001429991300544X-main.pdf?_tid=3bed999c-c5da-11e5-a3ae-00000aacb361&acdnat=1453997860_32-da06e835398491baf37333a2b5c44b
• 20 Stahl SM, Pradko JF, Haight BR. et al. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 2004; 6: 159-166 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/15361919
• 21 Panula P, Yang HY, Costa E. Histamine-containing neurons in the rat hypothalamus. Proc Natl Acad Sci U S A 1984; 81: 2572-2576 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/6371818
• 22 Xu C, Michelsen KA, Wu M. et al. Histamine innervation and activation of septohippocampal GABAergic neurones: involvement of local ACh release. J Physiol 2004; 561 (Pt 3): 657-670 . doi:10.1113/jphysiol.2004.071712
• 23 Mochizuki T, Okakura-Mochizuki K, Horii A. et al. Histaminergic modulation of hippocampal acetylcholine release in vivo. J Neurochem 1994; 62: 2275-2282 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/7910631
• 24 Laux G, Brunnauer A. Fahrtauglichkeit bei affektiven Störungen und unter Psychopharmaka. Nervenarzt 2014; 85: 822-828